Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Computational Drug Discovery

Background:

• Phosphodiesterase 4 (PDE4) inhibition is a therapeutic target for inflammatory pulmonary disorders such as asthma and COPD.
• Non-selective PDE4 inhibitors cause side effects like nausea and vomiting due to PDE4D inhibition in the brainstem.
• Selective PDE4B inhibition is desired to avoid emetic side effects while treating lung inflammation.

Purpose of the Study:

• To develop a selective PDE4B inhibitor for treating inflammatory pulmonary disorders.
• To identify drug candidates with improved safety profiles compared to non-selective PDE4 inhibitors.

Main Methods:

• A shared feature pharmacophore model was created and used for virtual screening of chemical databases (Maybridge, SPECS).
• Drug-like property filters were applied to select potential candidates.
• Molecular docking and 100ns molecular dynamics simulations were performed to assess binding affinity and stability.

Main Results:

• Nine potential drug candidates were identified through virtual screening.
• HTS04529 exhibited the highest affinity and selectivity for PDE4B over PDE4D in molecular docking.
• Molecular dynamics simulations confirmed tight and stable binding of HTS04529 to PDE4B, with a more stable complex than with PDE4D.

Conclusions:

• HTS04529 is a promising selective PDE4B inhibitor candidate for inflammatory pulmonary diseases.
• This selective inhibition strategy may overcome the emetic side effects associated with non-selective PDE4 inhibitors.
• Computational methods successfully identified a selective inhibitor with potential therapeutic applications.